ArticleFrontiers in pharmacology2025
BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models.
Fei Qin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it